An Observational Study Evaluating Patient Satisfaction and Quality of Life Associated With Switching Insulin (SWING)

Lilly

Status: Completed

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Analog or Human Insulin

Study type: Observational

Funder types: Industry

Identifiers

NCT00549887

11760

F3Z-EW-B003 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to estimate the direct costs associated with switching, in either direction, between a rapid-acting analog therapy and short-acting human insulin therapy within the first year following the switch. The additional goals are: 1)to assess the impact of a switch from or to a rapid-acting analog insulin therapy on patient treatment satisfaction, 2) to assess the impact of a switch from or to a rapid-acting analog insulin therapy on patient quality of life, 3) to assess the impact of switch from or to the rapid-acting analog insulin therapy on the quality of metabolic control and, 4) to estimate the total costs (direct and indirect) associated with switching, in either direction between rapid-acting analog and short-acting human insulin within the first year following the switch.

Enrollment: 2,459 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• are at least 18 years of age
• according to the clinical judgement of the investigator have been diagnosed with type II diabetes
• have presented within the normal course of care
• at the baseline visit are being treated with any therapy including a rapid-acting analog insulin component or any therapy including a short-acting human insulin component and are switching from one form of therapy to the other
• are not simultaneously participating in a study that includes an investigational drug or procedure at entry into the study
• have been fully informed and have given their written consent for the use of their data
• have a sufficient understanding of the primary language of the country such that they will be able to complete the questionnaires

Exclusion criteria

• no specific exclusion criteria exist for this study

Trial design

2,459 participants in 2 patient groups

Rapid acting to short acting

Description:

Patients on rapid-acting analog insulins who switch to short-acting human insulin

Treatment:

Drug: Analog or Human Insulin

Short acting to rapid acting

Description:

Patients on short-acting human insulins who switch to rapid-acting analog insulin

Treatment:

Drug: Analog or Human Insulin